Landscape Capital Management L.L.C. Grows Position in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Landscape Capital Management L.L.C. increased its stake in Vertex Pharmaceuticals by 171.0%, purchasing an additional 2,194 shares, bringing total holdings to 3,477 shares valued at approximately $1.686 million.
• Vertex Pharmaceuticals reported $4.52 earnings per share for the last quarter, surpassing consensus estimates, with revenue of $2.94 billion, reflecting an 11.3% year-over-year growth.
• Currently, 90.96% of Vertex Pharmaceuticals' stock is owned by institutional investors, indicating strong market support for the company.

Landscape Capital Management L.L.C. increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 171.0% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,477 shares of the pharmaceutical company's stock after purchasing an additional 2,194 shares during the quarter. Landscape Capital Management L.L.C.'s holdings in Vertex Pharmaceuticals were worth $1,686,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of VRTX. Aries Wealth Management purchased a new stake in Vertex Pharmaceuticals during the 1st quarter worth $293,000. Polar Asset Management Partners Inc. purchased a new stake in shares of Vertex Pharmaceuticals in the fourth quarter worth about $22,954,000. Brighton Jones LLC grew its stake in shares of Vertex Pharmaceuticals by 45.0% in the first quarter. Brighton Jones LLC now owns 6,421 shares of the pharmaceutical company's stock valued at $3,113,000 after buying an additional 1,994 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Vertex Pharmaceuticals by 25.1% during the 1st quarter. GAMMA Investing LLC now owns 5,002 shares of the pharmaceutical company's stock valued at $2,425,000 after buying an additional 1,005 shares during the period. Finally, Stanley Laman Group Ltd. acquired a new position in Vertex Pharmaceuticals during the 1st quarter worth approximately $486,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Up 0.8%

Shares of NASDAQ VRTX opened at $392.05 on Friday. The stock's 50 day moving average price is $434.34 and its two-hundred day moving average price is $459.10. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The stock has a market capitalization of $100.52 billion, a P/E ratio of 28.02 and a beta of 0.44.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. During the same period in the previous year, the business earned ($12.83) EPS. The business's quarterly revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Friday, August 22nd. Erste Group Bank downgraded shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 23rd. Truist Financial set a $490.00 price objective on shares of Vertex Pharmaceuticals and gave the company a "buy" rating in a research report on Tuesday, August 5th. Scotiabank lowered their target price on Vertex Pharmaceuticals from $442.00 to $438.00 and set a "sector perform" rating for the company in a research note on Tuesday, August 5th. Finally, Guggenheim cut their price target on Vertex Pharmaceuticals from $558.00 to $546.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $497.10.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs acquired 5,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The shares were purchased at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the purchase, the director directly owned 45,000 shares in the company, valued at $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 0.20% of the stock is currently owned by corporate insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.